NRX Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview

NRX Pharmaceuticals

12/05/2023 16:33

* NRX Pharmaceuticals Inc  NRXP.OQ   NRXP.O  is expected
to report
results on May 16.
    * 
    * ​Refinitiv's mean analyst estimate for NRX Pharmaceuticals
Inc
is for a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for NRX
Pharmaceuticals Inc is $4.75​, above​ its last closing price
of $0.61. ​​​

This summary was machine generated May 12 at 15:33 GMT.  All
figures in US dollars  unless otherwise stated